mutLBSgeneDB |
Gene summary for CDKL3 |
Gene summary |
Basic gene Info. | Gene symbol | CDKL3 |
Gene name | cyclin-dependent kinase-like 3 | |
Synonyms | NKIAMRE | |
Cytomap | UCSC genome browser: 5q31 | |
Type of gene | protein-coding | |
RefGenes | NM_001113575.1, NM_001300853.1,NM_016508.3, | |
Description | serine-threonine protein kinase NKIAMREserine/threonine-protein kinase NKIAMRE | |
Modification date | 20141207 | |
dbXrefs | MIM : 608459 | |
HGNC : HGNC | ||
Ensembl : ENSG00000006837 | ||
Vega : OTTHUMG00000186341 | ||
Protein | UniProt: Q8IVW4 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_CDKL3 | |
BioGPS: 51265 | ||
Pathway | NCI Pathway Interaction Database: CDKL3 | |
KEGG: CDKL3 | ||
REACTOME: CDKL3 | ||
Pathway Commons: CDKL3 | ||
Context | iHOP: CDKL3 | |
ligand binding site mutation search in PubMed: CDKL3 | ||
UCL Cancer Institute: CDKL3 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for CDKL3 |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | D83 | D83N | BRCA | 1 | V10 | V10L | LUAD | 1 | V10 | G8R | LUAD | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for CDKL3 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | D83 | D83N | -1.2083893 | V10 | G8R | -0.82639345 | V10 | V10L | -0.059093655 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for CDKL3 from PDB |
Top |
Differential gene expression and gene-gene network for CDKL3 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for CDKL3 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for CDKL3 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of CDKL3 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 38R | [4-({4-[(3-CYCLOPENTYL-1H-PYRAZOL-5-YL)AMINO] PYRIMIDIN-2-YL}AMINO)PHENYL]ACETONITRILE | 3zdu | A | V10 D83 |
Top |
Conservation information for LBS of CDKL3 |
Multiple alignments for Q8IVW4 in multiple species |
LBS | AA sequence | # species | Species | A31 | TGRIVAIKIFY | 2 | Mus musculus, Rattus norvegicus | A31 | TGQIVAIKIFY | 1 | Homo sapiens | C142 | GITKLCDFGFA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D143 | ITKLCDFGFAR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D175 | ELVLKDTSYGK | 2 | Homo sapiens, Mus musculus | D175 | ELVLKDTTYGK | 1 | Rattus norvegicus | D83 | VFEFIDHTVLD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D88 | DHTVLDELQHY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E129 | RDIKPENILVS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E80 | IHLVFEFIDHT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F79 | KIHLVFEFIDH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F81 | HLVFEFIDHTV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H223 | GNLTPHLHNIF | 2 | Mus musculus, Rattus norvegicus | H223 | GNLSPHLQNIF | 1 | Homo sapiens | H84 | FEFIDHTVLDE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I82 | LVFEFIDHTVL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L132 | KPENILVSQSG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N130 | DIKPENILVSQ | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T85 | EFIDHTVLDEL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V10 | ETLGKVGEGSY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V18 | GSYGTVMKCKH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |